Loading...
•
Dec 31, 2024
Ultragenyx Q4 2024 Earnings Report
Ultragenyx reported strong revenue growth in Q4 2024, driven by key product sales, but continued to post a net loss.
Key Takeaways
Ultragenyx delivered $164,877,000 in revenue for Q4 2024, a 29% YoY increase, primarily fueled by Crysvita and Dojolvi sales. Despite higher revenue, the company reported a net loss of $133,385,000, with increased R&D and operating expenses.
Total revenue grew 29% YoY to $164,877,000.
Crysvita and Dojolvi saw strong revenue growth of 23% and 34% YoY, respectively.
Net loss narrowed to $133,385,000, despite increased operating expenses.
2025 guidance projects revenue growth of 14-20% YoY.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Ultragenyx expects 2025 revenue growth of 14-20%, with focused investments in commercial launches and late-stage clinical programs.
Positive Outlook
- Total revenue projected to reach $640M-$670M.
- Crysvita revenue expected to grow to $460M-$480M.
- Dojolvi revenue guidance set at $90M-$100M.
- Expense management prioritized to reduce net cash burn.
- Multiple late-stage clinical trials progressing as planned.
Challenges Ahead
- Net losses likely to continue despite revenue growth.
- Higher R&D and SG&A expenses expected to persist.
- Regulatory uncertainties around gene therapy approvals.
- Dependence on partner collaborations for key products.
- Potential market challenges in expanding product adoption.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...